Herpes Simplex Virus (HSV-2)

• E.J. Schwartz and S.M. Blower. 2005. Predicting the potential individual level and population level impact of imperfect HSV-2 vaccines. Journal of Infectious Diseases 191(10): 1734-1746. [Full Text]

• C. Crespi, W.G. Cumberland, and S.M. Blower. 2005. A queueing model for chronic, recurrent conditions under panel observation. Biometrics 61(1): 193-198. [Full Text]

• S.M. Blower and Li Ma. 2004. Calculating the contribution of herpes simplex virus type 2 epidemics to increasing HIV incidence: treatment implications. Clinical Infectious Diseases 39(Suppl 5): S240-S247. [Full Text]

• S.M. Blower, A. Wald, H. Gershengorn, F. Wang, L. Corey. 2004. Targeting virological core groups: a new paradigm for controlling HSV-2 epidemics. Journal of Infectious Diseases 190. [Full Text]

• S.M. Blower. 2004. Modelling the genital herpes epidemic.  Herpes 11 Suppl 3: 138A-146A. [Full Text]

• C. Crespi, W.G. Cumberland, and S.M. Blower.  2004.  A within-host model of Herpes Simplex Virus.  Proceedings of the American Statistical Association, Bayesian Statistical Science.  Section, Alexanderia, VA: American Statistical Association. 

• H.B. Gershengorn, G.H. Darby and S.M. Blower. 2003. Predicting the emergence of drug-resistant HSV-2: new predictions. BMC Infectious Diseases: 3: 1. [Full Text]

• H.B. Gershengorn and S.M. Blower. 2000. The impact of antivirals and the emergence of drug resistance: HSV-2 epidemic control. AIDS Patient Care and STDs 14 (3): 133-42. [Full Text]

• S.M. Blower, T.C. Porco and G.H. Darby. 1998. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nature Medicine 4 (6): 673-678. [Full Text]